Effectiveness of difluprednate in addition to systemic therapy for the treatment of anterior scleritis

Simple item page
dc.catalogadorgrr
dc.contributor.authorLiberman Salazar, Paulina
dc.contributor.authorThorne, Jennifer
dc.contributor.authorBurkholder, Bryn
dc.contributor.authorBerkenstock, Meghan K.
dc.date.accessioned2023-10-10T20:19:30Z
dc.date.available2023-10-10T20:19:30Z
dc.date.issued2023
dc.description.abstractAim: To describe the effectiveness and side-effect profile of adding difluprednate therapy to patients with anterior scleritis being treated systemically.MethodsRetrospective chart review. Charts from all patients with anterior scleritis who were treated with topical difluprednate in addition to systemic therapy from 1 January 2018 to 1 January 2020 were reviewed. Data collected included: demographics, scleritis type, systemic diagnosis, presence of nodules or necrosis, changes in scleritis activity, intraocular pressure (IOP), number of difluprednate drops used, type of systemic treatment used, best-corrected visual acuity (BCVA) and lens status. The primary outcome was clinical resolution of scleritis. Secondary outcomes included BCVA loss & GE;2 lines, change in lens status or cataract surgery and IOP & GE;24 mm Hg.ResultsThirty-two patients (44 eyes) were analysed. The median age was 57 years (IQR 52, 72); 59% were female; 72% were Caucasian. An associated systemic disease was present in 59%. Systemic therapies used when difluprednate was added were: 65% immunosuppressive agents, 43% prednisone and 25% non-steroidal anti-inflammatory drugs. The addition of difluprednate resulted in clinical resolution in 79.6% of the treated eyes. Median time to inactivity was 9 weeks (IQR 5, 20). Eyes initially using 2-4 drops per day had a higher response rate (89%, p=0.005). Over a median follow-up of 34 weeks (IQR 21, 74), 11 eyes had IOP elevation; 6 eyes lost & GE;2 lines of BCVA, 5 eyes had cataract progression.ConclusionMost eyes treated with difluprednate achieved inactivity. The addition of difluprednate to systemic therapies provides an alternative to achieve control of inflammation.
dc.fechaingreso.objetodigital2023-20-10
dc.fuente.origenWOS
dc.identifier.doi10.1136/bjo-2022-322841
dc.identifier.eissn1468-2079
dc.identifier.issn0007-1161
dc.identifier.pubmedid37666642
dc.identifier.scopusidSCOPUS_ID:85170841864
dc.identifier.urihttps://doi.org/10.1136/bjo-2022-322841
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/75072
dc.identifier.wosidWOS:001062881800001
dc.information.autorucEscuela de Medicina; Liberman Salazar, Paulina; 0000-0002-1053-8651; 238017
dc.language.isoen
dc.nota.accesoContenido completo
dc.pagina.final5
dc.pagina.inicio1
dc.publisherBMJ Publishing Group
dc.revistaBritish Journal Of Ophtalmology
dc.rightsacceso abierto
dc.subjectSclera and episclera
dc.subjectInflammation
dc.subjectPharmacology
dc.subjectDrugs
dc.subjectIntraocular pressure
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleEffectiveness of difluprednate in addition to systemic therapy for the treatment of anterior scleritis
dc.typeartículo
sipa.codpersvinculados238017
sipa.indexWOS
sipa.trazabilidadWOS;2023-09-23
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Liberman_abs..pdf
Size:
79.84 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas